The estimated Net Worth of Preethi Sundaram is at least 614 千$ dollars as of 15 February 2024. Dr Sundaram owns over 16,667 units of Catalyst Pharmaceuticals Inc stock worth over 614,274$ and over the last 3 years he sold CPRX stock worth over 0$.
Dr has made over 5 trades of the Catalyst Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 16,667 units of CPRX stock worth 324,340$ on 15 February 2024.
The largest trade he's ever made was exercising 56,786 units of Catalyst Pharmaceuticals Inc stock on 11 November 2022 worth over 311,755$. On average, Dr trades about 12,778 units every 58 days since 2021. As of 15 February 2024 he still owns at least 31,566 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Dr Sundaram stock trades at the bottom of the page.
Dr. Preethi Sundaram Ph.D. is the Chief Product Devel. Officer at Catalyst Pharmaceuticals Inc.
Dr D is 46, he's been the Chief Product Devel. Officer of Catalyst Pharmaceuticals Inc since . There are 16 older and no younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Preethi's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over 35,595,986$ worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth 7,307,159$ . The most active insiders traders include Pharmaceutical Inc Biomarin、Patrick J Mcenany、Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 1,097,019$. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth 60,150$.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: